NBW Capital’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.32M | Sell |
33,703
-975
| -3% | -$101K | 0.93% | 43 |
|
|
2025
Q1 | $3.07M | Sell |
34,678
-9,208
| -21% | -$898K | 0.68% | 60 |
|
|
2024
Q4 | $3.83M | Buy |
43,886
+8,821
| +25% | +$808K | 0.71% | 61 |
|
|
2024
Q3 | $3.24M | Sell |
35,065
-15,965
| -31% | -$1.59M | 0.61% | 60 |
|
|
2024
Q2 | $5.5M | Buy |
51,030
+86
| +0.2% | +$8.61K | 1.08% | 41 |
|
|
2024
Q1 | $4.83M | Sell |
50,944
-1,791
| -3% | -$154K | 0.99% | 47 |
|
|
2023
Q4 | $4.86M | Sell |
52,735
-1,238
| -2% | -$80.2K | 1.07% | 45 |
|
|
2023
Q3 | $2.71M | Buy |
53,973
+1,433
| +3% | +$76.6K | 0.66% | 63 |
|
|
2023
Q2 | $3.32M | Sell |
52,540
-1,057
| -2% | -$57.5K | 0.77% | 62 |
|
|
2023
Q1 | $2.41M | Buy |
53,597
+33,009
| +160% | +$1.49M | 0.59% | 69 |
|
|
2022
Q4 | $902K | Sell |
20,588
-14,818
| -42% | -$711K | 0.23% | 71 |
|
|
2022
Q3 | $2.33M | Sell |
35,406
-539
| -1% | -$34.6K | 0.63% | 63 |
|
|
2022
Q2 | $1.82M | Buy |
35,945
+6,402
| +22% | +$375K | 0.5% | 69 |
|
|
2022
Q1 | $1.89M | Sell |
29,543
-231
| -0.8% | -$16.6K | 0.45% | 71 |
|
|
2021
Q4 | $3.19M | Buy |
29,774
+2,578
| +9% | +$270K | 0.71% | 63 |
|
|
2021
Q3 | $2.8M | Sell |
27,196
-267
| -1% | -$24.9K | 0.67% | 66 |
|
|
2021
Q2 | $2.42M | Buy |
27,463
+255
| +0.9% | +$23.4K | 0.59% | 68 |
|
|
2021
Q1 | $2.65M | Buy |
27,208
+1,562
| +6% | +$156K | 0.73% | 60 |
|
|
2020
Q4 | $2.88M | Sell |
25,646
-2,261
| -8% | -$238K | 0.87% | 53 |
|
|
2020
Q3 | $2.59M | Buy |
27,907
+855
| +3% | +$65.8K | 0.86% | 44 |
|
|
2020
Q2 | $2.11M | Buy |
27,052
+3,912
| +17% | +$265K | 0.76% | 52 |
|
|
2020
Q1 | $1.35M | Sell |
23,140
-1,426
| -6% | -$91.8K | 0.64% | 52 |
|
|
2019
Q4 | $1.97M | Buy |
24,566
+388
| +2% | +$29K | 0.56% | 63 |
|
|
2019
Q3 | $1.78M | Sell |
24,178
-956
| -4% | -$82.6K | 0.53% | 64 |
|
|
2019
Q2 | $2.37M | Sell |
25,134
-424
| -2% | -$35K | 0.65% | 61 |
|
|
2019
Q1 | $2.05M | Buy |
25,558
+120
| +0.5% | +$8.87K | 0.56% | 62 |
|
|
2018
Q4 | $1.37M | Buy |
25,438
+76
| +0.3% | +$4.62K | 0.49% | 61 |
|
|
2018
Q3 | $1.98M | Buy |
25,362
+4,512
| +22% | +$314K | 0.53% | 66 |
|
|
2018
Q2 | $1.32M | Buy |
20,850
+3,609
| +21% | +$287K | 0.38% | 66 |
|
|
2018
Q1 | $1.58M | Sell |
17,241
-7,641
| -31% | -$659K | 0.49% | 65 |
|
|
2017
Q4 | $1.88M | Sell |
24,882
-4,453
| -15% | -$313K | 0.49% | 60 |
|
|
2017
Q3 | $2.04M | Sell |
29,335
-5,313
| -15% | -$284K | 0.56% | 57 |
|
|
2017
Q2 | $1.76M | Sell |
34,648
-24,708
| -42% | -$1.05M | 0.49% | 62 |
|
|
2017
Q1 | $2.37M | Sell |
59,356
-226
| -0.4% | -$8.09K | 0.66% | 52 |
|
|
2016
Q4 | $1.67M | Buy |
59,582
+17,062
| +40% | +$514K | 0.48% | 56 |
|
|
2016
Q3 | $1.26M | Sell |
42,520
-478
| -1% | -$11.9K | 0.36% | 61 |
|
|
2016
Q2 | $871K | Sell |
42,998
-1,081
| -2% | -$19.6K | 0.27% | 61 |
|
|
2016
Q1 | $796K | Sell |
44,079
-541
| -1% | -$9.39K | 0.25% | 65 |
|
|
2015
Q4 | $1.18M | Sell |
44,620
-3,354
| -7% | -$75.5K | 0.36% | 68 |
|
|
2015
Q3 | $1.02M | Sell |
47,974
-11
| -0% | -$304 | 0.3% | 72 |
|
|
2015
Q2 | $1.27M | Buy |
+47,985
| New | +$1.37M | 0.29% | 67 |
|
Other funds holding BPMC
PCM
UOC
NBW Capital's BPMC Position: Q2 2025 in Review
NBW Capital reduced its Blueprint Medicines (BPMC) stake by 2.8% in Q2 2025, selling an estimated $101K and leaving 33,703 shares worth $4.32M. The position accounts for 0.93% of the portfolio, ranked #43.
NBW Capital first reported a position in BPMC in Q2 2015 and has held it in 41 quarters since. The position peaked at $5.5M in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.
- NBW Capital held 33,703 shares of Blueprint Medicines worth $4.32M as of Q2 2025.
- NBW Capital sold 975 Blueprint Medicines shares in Q2 2025, an estimated $101K.
- Blueprint Medicines made up 0.93% of NBW Capital's portfolio in Q2 2025, its #43 holding.
- NBW Capital first reported a position in Blueprint Medicines in Q2 2015 and has held it in 41 quarters since.
- NBW Capital's Blueprint Medicines position peaked at $5.5M in Q2 2024.
- 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.
Based on NBW Capital's 13F filing for Q2 2025, filed 13 Aug 2025.